MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting

Phase 3

MFOLFIRINOX vs. MFOLFOXMFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT05677490

Conditions

Advanced Esophageal Adenocarcinoma

Advanced Gastric Adenocarcinoma

Advanced Gastroesophageal Junction Adenocarcinoma

Clinical Stage III Esophageal Adenocarcinoma AJCC V8

Clinical Stage III Gastric Cancer AJCC V8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fluorouracil

Leucovorin Calcium

Oxaliplatin

Irinotecan

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-03-25.